Literature DB >> 9803677

Unrelated umbilical cord-blood stem cell transplantation: a report from Kanagawa Cord Blood Bank, Japan.

H Nishihira1, K Ohnuma, K Ikuta, K Isoyama, A Kinoshita, Y Toyoda, M Ohira, J Okamura, F Nakajima.   

Abstract

Umbilical cord-blood (CB) has been used as a source of hematopoietic stem cells in pediatric patients with sibling donors. As a result of the success with CB transplantation from sibling donors, pilot programs for the banking of unrelated donor CB were initiated in the organization of Kanagawa Cord Blood Bank, Japan in 1995. As of December 1997, unrelated donor CB was used to reconstitute hematopoiesis in seven patients aged 0.7-12.8 years, weighing 7-36 kg with high-risk leukemia (n = 5), myelodysplastic syndrome (n = 1), and immunodeficiency syndrome (n = 1). Engraftment of CB was achieved in six patients. The absolute neutrophil count reached 500/microliter in a median of 27 days; a platelet count of 20,000/microliter was reached by a median of 64 days in three patients who could be evaluated. Five patients are currently surviving. Grade I GVHD developed in three patients and grade III in one patient; no GVHD developed in three patients. Although only a small number of patients have been studied and the period of observation is too short to determine long-term survival, HLA-matched or HLA-mismatched CB from unrelated donors can provide an alternative source of hematopoietic reconstitution for clinical transplantation.

Entities:  

Mesh:

Year:  1998        PMID: 9803677     DOI: 10.1016/s0925-5710(98)00046-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  1 in total

1.  Hematopoietic capability of CD34+ cord blood cells: a comparison with CD34+ adult bone marrow cells.

Authors:  Takahiro Ueda; Makoto Yoshida; Hiroshi Yoshino; Kimio Kobayashi; Mariko Kawahata; Yasuhiro Ebihara; Mamoru Ito; Shigetaka Asano; Tatsutoshi Nakahata; Kohichiro Tsuji
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.